The ASGR1 knockout UM-UC-3 polyclonal cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ASGR1 gene in the human bladder cancer-derived UM-UC-3 cell line. This product constitutes a heterogeneous pool of cells with targeted gene disruption, enabling functional studies of ASGR1 loss in a carcinoma background without single-cell clonal isolation. The knockout model is generated by introducing CRISPR/Cas9-mediated double-strand breaks at the ASGR1 locus, leading to frameshift mutations and premature termination codons across the polyclonal population, thereby abolishing canonical ASGR1 protein expression and serving as a versatile loss-of-function tool.
The UM-UC-3 host cell line originates from a human transitional cell carcinoma of the bladder, representing an invasive urothelial carcinoma model that is extensively utilized in cancer biology, tumor progression studies, and drug sensitivity screening. This cell line maintains key characteristics of high-grade bladder malignancies, including metastatic potential and impaired apoptotic regulation, making it a clinically relevant platform for investigating molecular drivers of urothelial carcinoma. Its well-characterized genetic background enables precise downstream analyses of pathways often deregulated in bladder cancer.
ASGR1 encodes the major subunit of the asialoglycoprotein receptor (ASGPR), a C-type lectin that predominantly forms a heterooligomeric complex with ASGR2 on the hepatocyte surface but is also expressed in extrahepatic tissues. Upon binding desialylated glycoprotein ligands such as asialoorosomucoid and desialylated fetuin, the ASGPR?Cclathrin?CAP2 complex triggers receptor-mediated endocytosis, routing cargo to early endosomes and ultimately to lysosomes for degradation. This clearance mechanism is transcriptionally regulated by upstream factors including HNF4??, C/EBP??, STAT3, and IL-6, and functionally intersects with downstream effectors like JAK-STAT signaling components, Caspase-3, and NF-??B. Consequently, ASGR1 modulates glycoprotein homeostasis and exerts regulatory influences on cell survival, innate immunity, and apoptotic pathways.
In the UM-UC-3 bladder cancer context, loss of ASGR1 offers a model to dissect how glycoprotein receptor activity contributes to tumor-relevant processes. As ASGR1 may influence NF-??B and JAK-STAT cascades??both frequently activated in urothelial carcinoma??knockout cells can reveal mechanisms of immune evasion, resistance to apoptosis, and altered endocytic trafficking. Furthermore, because ASGR1 is implicated in substrates that can modify extracellular matrix interactions, this knockout model allows investigation of migration and invasion phenotypes essential for bladder cancer progression. The polyclonal nature preserves diversity in the edited population, mitigating clone-specific artifacts and better reflecting heterogeneous tumor responses.
This knockout tool is suited for an array of research applications, including fluorescent ligand uptake assays to quantify endocytosis defects, lysosomal activity measurements using fluorogenic substrates, and immunofluorescence to track ASGPR complex assembly. Functional studies may employ Western blotting and RT-qPCR to confirm gene disruption and assess downstream signaling molecules like phosphorylated STAT3 or NF-??B. High-content assays such as RNA-seq, flow cytometry for apoptosis, and phospho-signaling arrays enable global profiling of ASGR1-dependent networks. Additionally, migration and invasion assays can link ASGR1 loss to metastatic behavior, while drug discovery screens may exploit the polyclonal cells to validate ASGR1 as a therapeutic target in bladder cancer. For further technical details or customized applications, please contact Ascent Research.
